Passar para o conteúdo principal

Conexão rápida

CPHI Milan 2024

Connect with our API experts and explore industry-leading solutions.

Meet us at booth 24A41

October 08 - 10, 2024
Fiera Milano, Italy
Schedule a meeting
Verified

Our Team at CPHI Milan 2024

About Dr.Reddy’s API Business

We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 150+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.

Dr. Reddy's API  business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.

  • 250+ APIs

  • 8 Manufacturing sites

  • More than 1873 drug master files across global markets.

  • Over 325 ANDAs

  • More than 1000 patents field, and more than 70 own patents granted

  • Experience with complex APIs and formulations supporting early market entries.

  • Preferred pharma API supplier for pharma companies in more than 80 countries.

Sustainability is deeply embedded in our purpose and forms the core of our organization.

Our journey began with APIs in 1984, and we evolved from small molecules to large molecules and from APIs to finished formulations over the decades. Amidst this evolution, what has remained constant at the heart of our organization is a deep commitment to patients and the customers we serve through our core principles of collaboration and sustainability.

By the end of FY2024, we had served over 700 million patients and continue our endeavours to reach over 1.5 billion patients globally by 2030. This means almost one in every five people on this planet will use Dr. Reddy’s product or service. The health of people is strongly linked to the health of our planet. That's why our integrated report also shows how sustainability and business are strongly linked.

What we achieved in the past year:

 

Our Plants

About CPHI Milan 2024

CPHI Milan is a global pharmaceutical event uniting the pharmaceutical community to advance human health. With a history spanning 35 years, the event has become a cornerstone for fostering connections and inspiring partnerships across the industry. CPHI Milan is a platform for professionals to engage with the latest innovations, share knowledge, and collaborate on projects that shape the future of pharmaceuticals.

Key Highlights of CPHI Milan 2024:

  • Global Participation: The event expects to welcome 62,000 attendees and 2,400 exhibitors from 168+ countries, demonstrating its significant international reach.

  • Diverse Exhibition: Attendees can explore a wide range of products and services across various pharmaceutical sectors.

  • Networking Opportunities: CPHI Milan offers numerous opportunities for attendees to connect, build relationships, and forge partnerships.

  • Knowledge Exchange: The event features conferences, seminars, and workshops where industry experts share insights and discuss the latest trends.

  • Celebration of 35 Years: CPHI Milan 2024 marks a special milestone, celebrating 35 years of uniting the pharma community.

Our Achievement (awards)

Company

Follow Us on

© 2024 Dr. Reddy’s Laboratories Ltd. All rights reserved.

Aviso Legal

Nenhuma informação neste catálogo - incluindo qualquer referência a qualquer produto ou serviço - constitui uma oferta de venda ou deve ser interpretada como uma oferta de venda. Os produtos protegidos por patentes válidas não são oferecidos ou fornecidos para uso comercial. No entanto, as quantidades de pesquisa de tais produtos podem ser oferecidas para fins de submissão regulatória, onde quer que existam tais isenções regulatórias. Os compradores devem fazer sua avaliação independente do cenário de patentes para seus respectivos mercados e serão responsáveis por todas as responsabilidades relacionadas à patente. Os produtos protegidos por patentes válidas na Índia não estão disponíveis para uso comercial, mas estariam disponíveis para os propósitos da Seção 107A.